N/A
N=22
Testing of a New Therapeutic Vibration Device to Reduce Neuromuscular Weakness in Hospitalized Patients
Critically Ill · Post Intensive Care Syndrome
Bottom Line
View on ClinicalTrials.gov: NCT03479008 ↗Enrolled (actual)
22
Serious AEs
0.0%
Results posted
May 2024
Primary outcome: Primary: Change in Regional Hemoglobin Oxygen Saturation — 75.65; 77.01; 73.83; 77.09 percent of oxygenation — p=<0.0001
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Therapeutic Vibration Device (Diagnostic_test)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Michigan
- Primary completion
- Mar 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Regional Hemoglobin Oxygen Saturation |
75.65; 77.01; 73.83; 77.09; 72.23; 74.15 | <0.0001 sig |
| PRIMARY VO2 and VCO2 |
3.19; 3.84; 2.54; 3.07 | <0.0001 sig |
| PRIMARY Energy Expenditure |
1.12; 1.35 | <0.0001 sig |
| PRIMARY Minute Variation |
7.09; 8.50 | <0.0001 sig |
| PRIMARY Tidal Volume |
0.55; 0.68 | 0.094 |
| PRIMARY EMG |
13.10; 62.67; 5.15; 11.59; 3.17; 7.14 | 0.011 sig |
Summary
Objective: Test the ability of vibration to produce physiologic, biochemical, and anatomic changes consistent with exercise that would help prevent the development of muscle weakness that occurs when patients are immobile for long periods of time.
Eligibility Criteria
Exclusion Criteria
- Known pregnancy
- Prisoner
Data sourced from ClinicalTrials.gov (NCT03479008). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.